Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more
Helixmith Co. Ltd (084990) - Total Liabilities
Latest total liabilities as of September 2025: ₩5.85 Billion KRW
Based on the latest financial reports, Helixmith Co. Ltd (084990) has total liabilities worth ₩5.85 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Helixmith Co. Ltd - Total Liabilities Trend (2010–2024)
This chart illustrates how Helixmith Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Helixmith Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Helixmith Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
SHG:600671
|
China | CN¥335.43 Million |
|
Becamex Infrastructure Development JSC
VN:IJC
|
Vietnam | ₫2.28 Trillion |
|
Hooker Furniture Corporation
NASDAQ:HOFT
|
USA | $70.48 Million |
|
Cool Company Oy
OL:CLCO
|
Norway | Nkr1.53 Billion |
|
Nanjing OLO Home Furnishing
SHG:603326
|
China | CN¥878.06 Million |
|
MNRB Holdings Bhd
KLSE:6459
|
Malaysia | RM10.37 Billion |
|
Federal Corp
TW:2102
|
Taiwan | NT$6.89 Billion |
|
Daqing Huake Co Ltd
SHE:000985
|
China | CN¥114.38 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Helixmith Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Helixmith Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Helixmith Co. Ltd (2010–2024)
The table below shows the annual total liabilities of Helixmith Co. Ltd from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩6.85 Billion | -90.68% |
| 2023-12-31 | ₩73.56 Billion | +97.41% |
| 2022-12-31 | ₩37.26 Billion | -34.80% |
| 2021-12-31 | ₩57.15 Billion | -71.68% |
| 2020-12-31 | ₩201.84 Billion | +14.76% |
| 2019-12-31 | ₩175.87 Billion | +16.96% |
| 2018-12-31 | ₩150.37 Billion | +907.27% |
| 2017-12-31 | ₩14.93 Billion | +110.01% |
| 2016-12-31 | ₩7.11 Billion | +108.25% |
| 2015-12-31 | ₩3.41 Billion | +28.48% |
| 2013-12-31 | ₩2.66 Billion | -24.95% |
| 2012-12-31 | ₩3.54 Billion | -65.81% |
| 2011-12-31 | ₩10.35 Billion | -38.67% |
| 2010-12-31 | ₩16.88 Billion | -- |